In Reply.
Division of Pulmonology, Department of Medicine, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Quebec, Canada; Division of Pulmonology, Department of Medicine, Hôpital Charles-LeMoyne, Montreal, Quebec, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Nadim
N
Srour
Regenerative Medicine Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Bernard
B
Thébaud
D000818:Animals; D001761:Bleomycin / Q000009:adverse effects*; D004195:Disease Models, Animal; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D011658:Pulmonary Fibrosis
D001761:Bleomycin